HC Wainwright & Co. Maintains Buy on Arcturus Therapeutics, Raises Price Target to $63
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and raised the price target from $60 to $63.
August 08, 2024 | 8:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Arcturus Therapeutics and raised the price target from $60 to $63.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive short-term price appreciation for Arcturus Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100